Everolimus for advanced renal cell carcinoma after previous treatment

  • Technology appraisal guidance
  • TA432
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1 Everolimus is recommended within its marketing authorisation as an option for treating advanced renal cell carcinoma that has progressed during or after treatment with vascular endothelial growth factor targeted therapy, only if the company provides it with the discount agreed in the patient access scheme.